Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
|Articles|August 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 8
- Volume 17
- Issue 8
Erbitux gains expanded approval in Europe
Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer.
Advertisement
Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer. Erbitux can now be used in European patients with EGFR-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy and also as a single agent in patients who have failed oxaliplatin (Eloxatin)-based and irinotecan (Camptosar)-based therapy, according to manufacturer Merck KGaA of Darmstadt, Germany.
European Commission approval was based on data from two randomized, controlled trials. In the phase III CRYSTAL study, patients with KRAS wild-type tumors had a 59% response rate with cetuximab/chemotherapy vs 43% for chemotherapy alone. In the phase II OPUS trial, response rates were 61% vs 37%, respectively.
Articles in this issue
over 18 years ago
An editor says farewellover 18 years ago
High cost of biologics takes a toll on hem/onc practicesover 18 years ago
FDA mandates changes to ESA labeling infoover 18 years ago
Poll results: Medical education falters on pain reliefover 18 years ago
Certification offered to rad oncs for care of dying patientsover 18 years ago
VA enlists ACR for RT accreditations; H&N date changeover 18 years ago
Docs deserve pay for cognitive skill setover 18 years ago
Creator of Herceptin goes Hollywood in TV biopicover 18 years ago
Avastin/sunitnib RCC trial closes after serious toxicitiesover 18 years ago
FDA cracks down on counterfeit cancer cure productsAdvertisement
Related to this article
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer.
Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5